Einarsson R - Search Results

1

Clinical utility of cytokeratins as tumor markers.

Barak V, Goike H, Panaretakis KW, Einarsson R. Barak V, et al. Among authors: einarsson r. Clin Biochem. 2004 Jul;37(7):529-40. doi: 10.1016/j.clinbiochem.2004.05.009. Clin Biochem. 2004. PMID: 15234234 Review.

2

Tumor markers in breast cancer- European Group on Tumor Markers recommendations.

Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P. Molina R, et al. Among authors: einarsson r. Tumour Biol. 2005 Nov-Dec;26(6):281-93. doi: 10.1159/000089260. Tumour Biol. 2005. PMID: 16254457 Free article. Review.

3

Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up.

van Dalen A, Favier J, Hallensleben E, Burges A, Stieber P, de Bruijn HW, Fink D, Ferrero A, McGing P, Harlozinska A, Kainz Ch, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R, Goike H. van Dalen A, et al. Among authors: einarsson r. Eur J Gynaecol Oncol. 2009;30(6):609-15. Eur J Gynaecol Oncol. 2009. PMID: 20099488

4

Non-invasive Detection of Bladder Cancer by UBC Rapid Test, Ultrasonography and Cytology.

Barak V, Itzkovich D, Einarsson R, Gofrit O, Pode D. Barak V, et al. Among authors: einarsson r. Anticancer Res. 2020 Jul;40(7):3967-3972. doi: 10.21873/anticanres.14389. Anticancer Res. 2020. PMID: 32620639

5

The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease.

Van Dalen A, Barak V, Cremaschi A, Gion M, Molina R, Namer M, Stieber P, Sturgeon C, Einarsson R. Van Dalen A, et al. Among authors: einarsson r. Int J Biol Markers. 1998 Jan-Mar;13(1):10-5. doi: 10.1177/172460089801300103. Int J Biol Markers. 1998. PMID: 9681294

6

S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.

Harpio R, Einarsson R. Harpio R, et al. Among authors: einarsson r. Clin Biochem. 2004 Jul;37(7):512-8. doi: 10.1016/j.clinbiochem.2004.05.012. Clin Biochem. 2004. PMID: 15234232 Review.

7

Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9.

Slesak B, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, van Dalen A, Einarsson R. Slesak B, et al. Among authors: einarsson r. Cancer. 2000 Jul 1;89(1):83-8. doi: 10.1002/1097-0142(20000701)89:1<83::aid-cncr12>3.0.co;2-j. Cancer. 2000. PMID: 10897004 Clinical Trial.

8

Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma.

Berglund A, Molin D, Larsson A, Einarsson R, Glimelius B. Berglund A, et al. Among authors: einarsson r. Ann Oncol. 2002 Sep;13(9):1430-7. doi: 10.1093/annonc/mdf220. Ann Oncol. 2002. PMID: 12196369 Free article.

9

TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.

Harłozinska A, Sedlaczek P, Van Dalen A, Rozdolski K, Einarsson R. Harłozinska A, et al. Among authors: einarsson r. Anticancer Res. 1997 Nov-Dec;17(6D):4473-8. Anticancer Res. 1997. PMID: 9494553

10

Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements.

Glimelius B, Hoffman K, Einarsson R, Pählman L, Graf W. Glimelius B, et al. Among authors: einarsson r. Acta Oncol. 1996;35(2):141-8. doi: 10.3109/02841869609098494. Acta Oncol. 1996. PMID: 8639308 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

130 results

Search Page